• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Nuvectis Pharma, Inc. - Common Stock (NQ:NVCT)

18.41 -10.12 (-35.45%)
Streaming Delayed Price Updated: 12:11 PM EDT, Jun 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,869,294
Open 20.83
Bid (Size) 18.38 (200)
Ask (Size) 18.46 (200)
Prev. Close 28.53
Today's Range 18.22 - 21.24
52wk Range 5.550 - 29.27
Shares Outstanding 25,676,798
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Traders are paying attention to the gapping stocks in Tuesday's session. ↗
Today 10:30 EDT
Via Chartmill
Tuesday's pre-market session: top gainers and losers ↗
Today 8:30 EDT
Via Chartmill

Performance

YTD
+116.4%
+116.4%
1 Month
+88.9%
+88.9%
3 Month
+145.9%
+145.9%
6 Month
+139.8%
+139.8%
1 Year
+146.5%
+146.5%

More News

Read More
Wondering what's happening in today's after-hours session? ↗
June 29, 2026
Via Chartmill
News headline image
Nuvectis Pharma Announces Proposed Public Offering of Common Stock
June 29, 2026
From Nuvectis Pharma, Inc.
Via GlobeNewswire
Keep an eye on the top gainers and losers in Wednesday's session. ↗
June 24, 2026
Via Chartmill
Here are the top movers in Wednesday's session. ↗
June 24, 2026
Via Chartmill
News headline image
Nuvectis Announces Strategic Portfolio Expansion via License Agreement for Ex-China Rights with Haisco Pharmaceutical Group for Two Potentially Best-In Class Clinical-Stage Compounds
June 22, 2026
From Nuvectis Pharma, Inc.
Via GlobeNewswire
News headline image
Nuvectis Pharma, Inc. To Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
May 14, 2026
From Nuvectis Pharma, Inc.
Via GlobeNewswire
News headline image
Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2026 American Association for Cancer Research Meeting
March 31, 2026
From Nuvectis Pharma, Inc.
Via GlobeNewswire
News headline image
Nuvectis Pharma Announces the Initiation of the Phase 1b Study of NXP900 in Combination with Osimertinib in Patients with NSCLC
December 17, 2025
From Nuvectis Pharma, Inc.
Via GlobeNewswire
News headline image
Nuvectis Pharma to Host a Virtual Key Opinion Leader Meeting to Discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, Including the Combination with Osimertinib in NSCLC
November 25, 2025
From Nuvectis Pharma, Inc.
Via GlobeNewswire
News headline image
Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights
November 04, 2025
From Nuvectis Pharma, Inc.
Via GlobeNewswire
News headline image
Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 27, 2025
From Nuvectis Pharma, Inc.
Via GlobeNewswire
News headline image
Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 16, 2025
From Nuvectis Pharma, Inc.
Via GlobeNewswire
News headline image
Nuvectis Pharma Appoints Biotech Executive Juan Sanchez, MD, to the Board of Directors
September 25, 2025
From Nuvectis Pharma, Inc.
Via GlobeNewswire
News headline image
Nuvectis Pharma to Participate at the H.C. Wainwright 27th Annual Global Investment Conference
September 04, 2025
From Nuvectis Pharma, Inc.
Via GlobeNewswire
News headline image
Nuvectis Pharma Announces the Initiation of the Phase 1b Program for NXP900
August 11, 2025
From Nuvectis Pharma, Inc.
Via GlobeNewswire
News headline image
Nuvectis (NVCT) Q2 Loss Widens 43% ↗
August 05, 2025
Via The Motley Fool
News headline image
Discover the top movers in Thursday's pre-market session. ↗
July 31, 2025
Via Chartmill
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
July 31, 2025
Via Benzinga
News headline image
Nuvectis Pharma Provides Final Clinical Data Update from the NXP800 Phase 1b Study in Ovarian Cancer and Reports Completion of the NXP900 Phase 1a Dose Escalation Study
July 31, 2025
From Nuvectis Pharma, Inc.
Via GlobeNewswire
News headline image
Nuvectis Pharma Announces Successful Completion of a Drug-Drug Interaction Study in Healthy Volunteers Supporting NXP900's Potential as a Combination Partner with Leading Therapies
July 08, 2025
From Nuvectis Pharma, Inc.
Via GlobeNewswire
News headline image
Smart Money is Quietly Loading Up On This $160M Oncology Stock — Is Nuvectis Pharma the Next Breakout Biotech? (NASDAQ: NVCT)
June 20, 2025
Via News Direct
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
May 27, 2025
Via Benzinga
News headline image
Nuvectis Pharma to Present at the H.C. Wainwright BioConnect Investor Conference
May 16, 2025
From Nuvectis Pharma, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Nuvectis Pharma, Inc. - Common Stock publicly traded?
Yes, Nuvectis Pharma, Inc. - Common Stock is publicly traded.
What exchange does Nuvectis Pharma, Inc. - Common Stock trade on?
Nuvectis Pharma, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Nuvectis Pharma, Inc. - Common Stock?
The ticker symbol for Nuvectis Pharma, Inc. - Common Stock is NVCT on the Nasdaq Stock Market
What is the current price of Nuvectis Pharma, Inc. - Common Stock?
The current price of Nuvectis Pharma, Inc. - Common Stock is 18.41
When was Nuvectis Pharma, Inc. - Common Stock last traded?
The last trade of Nuvectis Pharma, Inc. - Common Stock was at 06/30/26 12:11 PM ET
What is the market capitalization of Nuvectis Pharma, Inc. - Common Stock?
The market capitalization of Nuvectis Pharma, Inc. - Common Stock is 472.84M
How many shares of Nuvectis Pharma, Inc. - Common Stock are outstanding?
Nuvectis Pharma, Inc. - Common Stock has 473M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap